Jazz Pharmaceuticals announced it will acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones. The acquisition includes ABS-1230, a novel precision therapy targeting KCNT1+ epilepsy, a rare and severe genetic epilepsy with no approved treatments. ABS-1230 has shown promising early clinical results and benefits from FDA designations to speed development. The deal strengthens Jazz's rare epilepsy portfolio and is expected to close by Q4 2026, with Jazz also gaining a minority stake in a new spin-out company focused on other rare neurological diseases.
Sunoco LP has evolved into a diversified multinational platform combining fuel distribution, pipelines, terminals, convenience stores, and refining. In Q2 2026, the company reported a net income of $283 million and an adjusted EBITDA of $982 million,...
In Q2 2026, TRON processed $2.1 trillion in USDT transfers, with its stablecoin market cap reaching a record $89.2 billion. USDT supply on TRON ended the quarter at $87.9 billion, making it the largest blockchain host for circulating USDT, surpassing...
Bitcoin is approaching a breakeven point for short-term holders, with the 30-day STH SOPR close to 1.0, signaling reduced selling pressure. However, record long exposure in the derivatives market, with 361,000 BTC held long, raises the risk of increa...
Boston Scientific reported solid Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth, driven by strong international demand, particularly in electrophysiology and WATCHMAN devices. Despite facing growth headwinds in the U.S., the com...
Equitable Holdings is rated a Strong Buy due to strong financials, a favorable interest rate environment, and the upcoming merger with Corebridge. The company is expected to generate $1.8 billion in cash and return at least $4.30 per share in capital...
